NCT01045902

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 139 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.

Conditions

• Pneumonia, Aspiration
• Lung Abscess

Interventions

Type	Name	Description
DRUG	Avelox (Moxifloxacin, BAY12-8039)	Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
DRUG	Sulbactam/Ampicillin	Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid

Timeline

• Start date: 2001-02-01
• Completion: 2005-01-01
• First posted: 2010-01-11
• Last updated: 2010-01-11

Locations

15 sites across 1 country: Germany